Discontinued — last reported Q3 '21

Other

Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value

Pfizer Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value increased by 14.0% to $2.04B in Q1 2026 compared to the prior quarter.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ4 2017
Last reportedQ3 2021
Metric ID: other_fair_value_measurement_with_unobservable_inputs_re_2a44fd

Historical Data

4 periods
 Q4 '24Q1 '25Q4 '25Q1 '26
Value$517.00M$477.00M$1.79B$2.04B
QoQ Change—-7.7%+275.3%+14.0%
YoY Change——+246.2%+327.9%
Range$477.00M – $2.04B
Avg YoY Growth+287.1%
Median YoY Growth+287.1%
Current Streak2 quarters growth

Frequently Asked Questions

What is Pfizer's fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value?
Pfizer (PFE) reported fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value of $2.04B in Q1 2026.